Aberrant activation of the hedgehog signaling pathway in malignant hematological neoplasms

Chi Young Ok, Rajesh Ramachandra Singh, Francisco Vega

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

The hedgehog (HH) signaling pathway is a highly regulated signaling pathway that is important not only for embryonic development, tissue patterning, and organogenesis but also for tissue repair and the maintenance of stem cells in adult tissues. In the adult hematopoietic system, HH signaling regulates intrathymic T-cell development, and it is one of the survival signals provided by follicular dendritic cells to prevent apoptosis in germinal center B cells. HH signaling is required for primitive hematopoiesis; however, conflicting data have been reported regarding the role of the HH pathway in adult hematopoiesis. Inappropriate activation of the HH signaling pathway occurs in several human cancers, including hematological neoplasms. Emerging data demonstrate abnormal HH pathway activation in chronic lymphocytic leukemia/small lymphocytic lymphoma, plasma cell myeloma, mantle cell lymphoma, diffuse large B-cell lymphoma, ALK-positive anaplastic large cell lymphoma, chronic myelogenous leukemia, and acute leukemias. In these neoplasms, HH signaling promotes proliferation and survival, contributes to the maintenance of cancer stem cells, and enhances tolerance or resistance to chemotherapeutic agents. Here, we review current understanding of HH signaling, its role in the pathobiology of hematological malignancies, and its potential as a therapeutic target to treat malignant hematological neoplasms.

Original languageEnglish
Pages (from-to)2-11
Number of pages10
JournalAmerican Journal of Pathology
Volume180
Issue number1
DOIs
StatePublished - Jan 1 2012
Externally publishedYes

Fingerprint

Hematologic Neoplasms
Hematopoiesis
B-Cell Chronic Lymphocytic Leukemia
Maintenance
Follicular Dendritic Cells
Anaplastic Large-Cell Lymphoma
Mantle-Cell Lymphoma
Hematopoietic System
Adult Stem Cells
Germinal Center
Survival
Organogenesis
Neoplastic Stem Cells
Lymphoma, Large B-Cell, Diffuse
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Multiple Myeloma
Embryonic Development
Neoplasms
Leukemia
B-Lymphocytes

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Aberrant activation of the hedgehog signaling pathway in malignant hematological neoplasms. / Ok, Chi Young; Singh, Rajesh Ramachandra; Vega, Francisco.

In: American Journal of Pathology, Vol. 180, No. 1, 01.01.2012, p. 2-11.

Research output: Contribution to journalArticle

@article{b0aa232229874ba7a010b05ab03efba0,
title = "Aberrant activation of the hedgehog signaling pathway in malignant hematological neoplasms",
abstract = "The hedgehog (HH) signaling pathway is a highly regulated signaling pathway that is important not only for embryonic development, tissue patterning, and organogenesis but also for tissue repair and the maintenance of stem cells in adult tissues. In the adult hematopoietic system, HH signaling regulates intrathymic T-cell development, and it is one of the survival signals provided by follicular dendritic cells to prevent apoptosis in germinal center B cells. HH signaling is required for primitive hematopoiesis; however, conflicting data have been reported regarding the role of the HH pathway in adult hematopoiesis. Inappropriate activation of the HH signaling pathway occurs in several human cancers, including hematological neoplasms. Emerging data demonstrate abnormal HH pathway activation in chronic lymphocytic leukemia/small lymphocytic lymphoma, plasma cell myeloma, mantle cell lymphoma, diffuse large B-cell lymphoma, ALK-positive anaplastic large cell lymphoma, chronic myelogenous leukemia, and acute leukemias. In these neoplasms, HH signaling promotes proliferation and survival, contributes to the maintenance of cancer stem cells, and enhances tolerance or resistance to chemotherapeutic agents. Here, we review current understanding of HH signaling, its role in the pathobiology of hematological malignancies, and its potential as a therapeutic target to treat malignant hematological neoplasms.",
author = "Ok, {Chi Young} and Singh, {Rajesh Ramachandra} and Francisco Vega",
year = "2012",
month = "1",
day = "1",
doi = "10.1016/j.ajpath.2011.09.009",
language = "English",
volume = "180",
pages = "2--11",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Aberrant activation of the hedgehog signaling pathway in malignant hematological neoplasms

AU - Ok, Chi Young

AU - Singh, Rajesh Ramachandra

AU - Vega, Francisco

PY - 2012/1/1

Y1 - 2012/1/1

N2 - The hedgehog (HH) signaling pathway is a highly regulated signaling pathway that is important not only for embryonic development, tissue patterning, and organogenesis but also for tissue repair and the maintenance of stem cells in adult tissues. In the adult hematopoietic system, HH signaling regulates intrathymic T-cell development, and it is one of the survival signals provided by follicular dendritic cells to prevent apoptosis in germinal center B cells. HH signaling is required for primitive hematopoiesis; however, conflicting data have been reported regarding the role of the HH pathway in adult hematopoiesis. Inappropriate activation of the HH signaling pathway occurs in several human cancers, including hematological neoplasms. Emerging data demonstrate abnormal HH pathway activation in chronic lymphocytic leukemia/small lymphocytic lymphoma, plasma cell myeloma, mantle cell lymphoma, diffuse large B-cell lymphoma, ALK-positive anaplastic large cell lymphoma, chronic myelogenous leukemia, and acute leukemias. In these neoplasms, HH signaling promotes proliferation and survival, contributes to the maintenance of cancer stem cells, and enhances tolerance or resistance to chemotherapeutic agents. Here, we review current understanding of HH signaling, its role in the pathobiology of hematological malignancies, and its potential as a therapeutic target to treat malignant hematological neoplasms.

AB - The hedgehog (HH) signaling pathway is a highly regulated signaling pathway that is important not only for embryonic development, tissue patterning, and organogenesis but also for tissue repair and the maintenance of stem cells in adult tissues. In the adult hematopoietic system, HH signaling regulates intrathymic T-cell development, and it is one of the survival signals provided by follicular dendritic cells to prevent apoptosis in germinal center B cells. HH signaling is required for primitive hematopoiesis; however, conflicting data have been reported regarding the role of the HH pathway in adult hematopoiesis. Inappropriate activation of the HH signaling pathway occurs in several human cancers, including hematological neoplasms. Emerging data demonstrate abnormal HH pathway activation in chronic lymphocytic leukemia/small lymphocytic lymphoma, plasma cell myeloma, mantle cell lymphoma, diffuse large B-cell lymphoma, ALK-positive anaplastic large cell lymphoma, chronic myelogenous leukemia, and acute leukemias. In these neoplasms, HH signaling promotes proliferation and survival, contributes to the maintenance of cancer stem cells, and enhances tolerance or resistance to chemotherapeutic agents. Here, we review current understanding of HH signaling, its role in the pathobiology of hematological malignancies, and its potential as a therapeutic target to treat malignant hematological neoplasms.

UR - http://www.scopus.com/inward/record.url?scp=83455258135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83455258135&partnerID=8YFLogxK

U2 - 10.1016/j.ajpath.2011.09.009

DO - 10.1016/j.ajpath.2011.09.009

M3 - Article

VL - 180

SP - 2

EP - 11

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 1

ER -